Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
News|Articles|November 5, 2025
Conference Preview: NASPGHAN Annual Meeting 2025
Author(s)Joshua Fitch
Fact checked by: HCPLive staff
This preview of the 2025 NASPGHAN Annual Meeting highlights sessions and expert discussions on pediatric gastroenterology, hepatology, and nutrition covered by HCPLive.
Advertisement
Advertisement
The North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) is holding its Annual Meeting from November 5–8, 2025, at the Sheraton Grand Chicago in Chicago, Illinois. Over the course of this four-day conference, pediatric gastroenterologists, hepatologists, nutrition specialists, and leading experts will gather to share the latest data, clinical updates, and evidence-based discussions across gastrointestinal, liver, and nutritional disorders in children.
Related to this article
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
Hepatology in Q3 2026: brelovitug and lonafarnib advance in hepatitis D, plus Wilson disease, MASH, and US alcohol use updates.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Advertisement
Advertisement